TABLE 1.
Bacterial strains and plasmids used in this study
| E. coli strain or plasmid | Relevant genotype | Source or reference |
|---|---|---|
| BL-21 | F−dcm ompT hsdS(rB− mB−) gal | Stratagene |
| MC4100hns | hns::kan | 27 |
| MG1655slyA::kan | slyA::kan | J. Green |
| MG1655slyA::Cmr | slyA::Cmr | Peng Xue |
| P90C | F−ara Δ(lac pro) thi-1 | 29 |
| P90Chns::kan | P90C × P1(MC4100hns) | This study |
| P90CslyA::kan | P90C × P1(MG1655slyA::kan) | This study |
| P90Chns::kan slyA::Cmr | P90Chns::kan × P1(MG1655slyA::Cmr) | This study |
| Plasmids | ||
| pACYC184 | Cloning vector | 5 |
| pACYC184-SlyA | pACYC184 containing slyA coding region and promoter | 6 |
| pET22b | His fusion expression vector | Novagen |
| pET22b-H-NS | pET22b, hns+ | 6 |
| pGEX-6P-1 | GST fusion expression vector | Amersham Biosciences |
| pRS415 | lacZ promoter-probe vector | 29 |
| pBluescriptSK+ | Cloning vector | Stratagene |
| pRSA | pRS415+PR3 (−320 to +741) | This study |
| pRSB | pRS415 + the sequences (+1 to +741) 3′ to PR3 | This study |
| pRSC | pRS415+PR3 (−320 to +1) | This study |
| pRSA-1 | 56-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-2 | 107-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-3 | 216-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-4 | 276-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-5 | 299-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-6 | 361-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-11 | 456-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-12 | 658-bp deletion of pRSA (Fig. 2) | This study |
| pRSA-17 | 706-bp deletion of pRSA (Fig. 2) | This study |
| pBlue-C | pSK+ with a cloned 356-bp PCR product (−320 to +36) | This study |
| pBlue-H | pSK+ with a cloned 245-bp PCR product (+1 to +246) | This study |